Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Sarina Isenberg, PhD Candidate, of the Johns Hopkins Bloomberg School of Public Health, discusses the cost savings of a comprehensive hospital-based palliative care program. (Abstract 2)
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
